Research graph
References from Early molecular changes and a pivotal transition define triple-negative breast cancer progression in a murine model: a stage-resolved transcriptomic study. Local targets link to admitted publications; unresolved targets remain external evidence.
Advanced and Metastatic Triple Negative Breast Cancer—Potential New Treatment
10.3390/cancers17071183 · 2025 · External reference
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
10.1038/nrclinonc.2016.66 · 2016 · External reference
What is triple-negative breast cancer?
10.1016/j.ejca.2008.09.034 · 2008 · External reference
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
10.1172/jci45014 · 2011 · External reference
Classifications of triple-negative breast cancer: insights and current therapeutic approaches
10.1186/s13578-025-01359-0 · 2025 · External reference
Asporin increases the extracellular matrix cross-links and inhibits the cancer cell migration
10.1177/10104283241313441 · 2025 · External reference
Rotating magnetic field downregulating type XI collagen to suppress triple-negative breast cancer metastasis by inactivating the ITGB1/FAK/YAP signaling pathway
10.1016/j.ijbiomac.2025.149677 · 2026 · External reference
The role of tumor microenvironment and immune cell crosstalk in triple-negative breast cancer (TNBC): Emerging therapeutic opportunities
10.1016/j.canlet.2025.217865 · 2025 · External reference
Metabolic-Pathway-Based Subtyping of Triple-Negative Breast Cancer Reveals Potential Therapeutic Targets
10.1016/j.cmet.2020.10.012 · 2021 · External reference
Metabolic reprogramming in triple-negative breast cancer
10.20892/j.issn.2095-3941.2019.0210 · 2020 · External reference
Watching cancer begin: emerging tools to visualize the first steps of tumorigenesis
10.1016/j.trecan.2026.02.007 · 2026 · External reference
Advances in the Understanding of the Pathogenesis of Triple-Negative Breast Cancer
10.1002/cam4.70410 · 2024 · External reference
Hallmarks of Cancer: New Dimensions
10.1158/2159-8290.cd-21-1059 · 2022 · External reference
Heterogeneity and transcriptional drivers of triple-negative breast cancer
10.1016/j.celrep.2023.113564 · 2023 · External reference
Multi-Omics Characterization of the 4T1 Murine Mammary Gland Tumor Model
10.3389/fonc.2020.01195 · 2020 · External reference
Imagable 4T1 model for the study of late stage breast cancer
10.1186/1471-2407-8-228 · 2008 · External reference
An Orthotopic Mouse Model of Spontaneous Breast Cancer Metastasis
10.3791/54040 · 2016 · External reference
Precision modeling of gall bladder cancer patients in mice based on orthotopic implantation of organoid-derived tumor buds
10.1038/s41389-021-00322-1 · 2021 · External reference
Advances in the Understanding of the Pathogenesis of Triple-Negative Breast Cancer
10.1002/cam4.70410 · 2024 · External reference
A shared transcriptional program in early breast neoplasias despite genetic and clinical distinctions
10.1186/gb-2014-15-5-r71 · 2014 · External reference
A potential driver of tumor metastasis
10.1016/j.ijbiomac.2025.141752 · 2025 · External reference
Metabolic reprogramming in breast cancer: Pathways driving progression, drug resistance, and emerging therapeutics. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
10.1016/j.bbcan.2025.189396 · 2025 · External reference
Metabolic Reprogramming in Breast Cancer and Its Therapeutic Implications
10.3390/cells8020089 · 2019 · External reference
Metabolic reprogramming and therapeutic resistance in primary and metastatic breast cancer
10.1186/s12943-024-02165-x · 2024 · External reference
On metabolic reprogramming and tumor biology: A comprehensive survey of metabolism in breast cancer
10.18632/oncotarget.11759 · 2016 · External reference
Telomere DNA content and allelic imbalance demonstrate field cancerization in histologically normal tissue adjacent to breast tumors
10.1002/ijc.21815 · 2006 · External reference
Markers of fibrosis and epithelial to mesenchymal transition demonstrate field cancerization in histologically normal tissue adjacent to breast tumors
10.1002/ijc.25788 · 2011 · External reference
A risk-associated Active transcriptome phenotype expressed by histologically normal human breast tissue and linked to a pro-tumorigenic adipocyte population
10.1186/s13058-020-01322-6 · 2020 · External reference
Mapping genomic and transcriptomic alterations spatially in epithelial cells adjacent to human breast carcinoma
10.1038/s41467-017-01357-y · 2017 · External reference
10.1016/b978-0-443-26635-5.00011-0
10.1016/b978-0-443-26635-5.00011-0 · 2025 · External reference
Collagen remodeling in breast cancer progression: from molecular mechanisms to diagnostic and therapeutic opportunities
10.1007/s12094-026-04450-1 · 2026 · External reference
Transcriptomic dynamics of breast cancer progression in the MMTV-PyMT mouse model
10.1186/s12864-017-3563-3 · 2017 · External reference
10.1073/pnas.1911193116
10.1073/pnas.1911193116 · 2019 · External reference
Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments
10.1186/s12943-023-01744-8 · 2023 · External reference
Prominent protumoral cellular compartments of the tumor microenvironment in triple-negative breast cancer
10.3389/fcell.2025.1668583 · 2026 · External reference
Osteopontin mediates an MZF1–TGF-β1-dependent transformation of mesenchymal stem cells into cancer-associated fibroblasts in breast cancer
10.1038/onc.2014.410 · 2015 · External reference
